Chernausek S D, Underwood L E, Van Wyk J J
Endocrinology. 1982 Nov;111(5):1534-8. doi: 10.1210/endo-111-5-1534.
The binding of 125I-iodinated human GH ([125I]iodo-hGH) to crude, membrane-rich preparations from the livers of thyroidectomized male rats was examined to determine if alterations in GH binding might explain hypothyroid-induced growth failure. Membrane preparations from chronically hypothyroid rats bound nearly twice as much labeled hGH (12.8 +/- 2.5%; mean +/- 1 SD) as those from normal rats (6.6 +/- 1.4%) or thyroxine-treated thyroidectomized animals (7.0 +/- 1.1%). Binding by membrane preparations from hypothyroid rats treated with hGH for 2 weeks was 12.3%. By Scatchard analysis the apparent affinities of the membrane preparations for hGH were relatively constant (Ka = 2.30-2.88 X 10(9) M-1) among the experimental groups. Ovine PRL was only 1.4% as potent as hGH in displacing [125I]iodo-hGH from the liver preparations, indicating that hGH was bound primarily to somatogenic sites. Since administration of hGH did not reduce the binding of [125I]iodo-hGH, it is unlikely that the increase in hGH binding in hypothyroidism is mediated by a reduction in the ambient GH concentration. Furthermore, this increase in [125I]iodo-hGH binding indicates that an alteration in binding of GH to its receptor probably does not mediate either the low somatomedin levels or the growth failure that result from hypothyroidism.
研究了125I标记的人生长激素([125I]碘代-hGH)与甲状腺切除的雄性大鼠肝脏富含膜的粗制品的结合情况,以确定生长激素结合的改变是否可以解释甲状腺功能减退引起的生长障碍。来自慢性甲状腺功能减退大鼠的膜制品结合的标记hGH几乎是正常大鼠(6.6±1.4%)或甲状腺素治疗的甲状腺切除动物(7.0±1.1%)的两倍(12.8±2.5%;平均值±1标准差)。用hGH治疗2周的甲状腺功能减退大鼠的膜制品结合率为12.3%。通过Scatchard分析,各实验组中膜制品对hGH的表观亲和力相对恒定(Ka = 2.30 - 2.88×109 M-1)。绵羊催乳素在从肝脏制品中取代[125I]碘代-hGH方面的效力仅为hGH的1.4%,这表明hGH主要结合到促生长位点。由于给予hGH并没有降低[125I]碘代-hGH的结合,甲状腺功能减退时hGH结合增加不太可能是由周围生长激素浓度降低介导的。此外,[125I]碘代-hGH结合的这种增加表明,生长激素与其受体结合的改变可能不是甲状腺功能减退导致的生长介素水平降低或生长障碍的介导因素。